Introduction
Mood disorders including bipolar disorder, major depression and anxiety disorders are highly heritable, indicating that genetic or heritable epigenetic components contribute to risk of developing disease (Cross-Disorder Group of the Psychiatric Genomics et al., 2013; Genetics of Personality et al., 2015; McCarthy et al., 2014; Song et al., 2015) .
Large genome-wide association studies and whole genome sequencing studies have identified common and rare variants which implicate shared neurobiological pathways including glutamate neurotransmission involving NMDA, AMPA and KAR receptors (Singh et al., 2017; Teng et al., 2017; Witt et al., 2017) . De novo and inherited structural variants and point mutations have been identified as risk variants within glutamate subunit receptor genes (Frank et al., 2011; Hamdan et al., 2011; Kirov et al., 2012) . These genetic findings support the view that disruption of the glutamatergic system contributes to the pathophysiology of mental illnesses.
Kainate receptors are ionotropic glutamate receptors involved in cellular functions necessary for learning and memory, such as synaptic plasticity, long-term potentiation and neurotransmission (Bortolotto et al., 1999; Bortolotto et al., 2005; Lerma et al., 2013; Schmitz et al., 2003; Sihra et al., 2014; Sihra et al., 2013) . They are composed of tetrameric combinations of five subunits (GluK1-GluK5; encoded by GRIK1-GRIK5) and modulated by auxiliary proteins Neto1 and Neto2 (Han et al., 2016; Jane et al., 2009; Kristensen et al., 2016; Lerma et al., 2001; Li et al., 2016; Traynelis et al., 2010) . We have previously reported GRIK4/GluK4 as a breakpoint gene disrupted in a complex chromosomal rearrangement in a patient diagnosed with schizophrenia comorbid with learning disability (Pickard et al., 2008; Pickard et al., 2006) . Subsequent case control genetic studies led to the identification of a 14 base pair deletion variant (indel) (rs869187535) within the 3' untranslated region of the gene which was negatively associated with bipolar disorder (Knight et al., 2012; Pickard et al., 2006) . A significant increase in RNA and protein GluK4 expression in the frontal cortex and hippocampus correlating with the deletion allele provided some indication that subunit availability in specific neuronal populations such as the CA3 mossy fibre region might underlie this protective effect (Knight et al., 2012; Pickard et al., 2008) . Consistent with this model, individuals with the deletion allele were reported to show greater left hippocampal activation than insertion homozygotes during a cognitive face processing task (Whalley et al., 2009) .
Rodent behavioural studies have provided additional evidence that GluK4 receptor subunit function contributes to neuropsychiatric phenotypes and memory function. For example, GluK4 knockout mice demonstrate hippocampal-dependent cognitive impairments, marked hyperactivity and impaired pre-pulse inhibition which reflect aspects of a schizophrenic phenotype (Lowry et al., 2013) , whereas mice overexpressing Grik4 in the forebrain show anhedonia, depression, anxiety, altered social interaction and synaptic transmission, features consistent with an autism spectrum disorder phenotype (Aller et al., 2015) .
Large scale genome-wide pharmacogenetics studies have also reported an association between variants within GluK4 and response to antidepressant treatment. For instance, variants in the 3' region of GluK4 identified in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical trial were found to affect patients' response to citalopram antidepressant treatment (Paddock et al., 2007) . Subsequently, intronic variants within GluK4 have now been consistently reported as moderating both antidepressant and antipsychotic efficacy and tolerability (Drago et al., 2013) .
The aim of this study was to compare cognitive performance in subjects carrying the protective 3'UTR GluK4 deletion with subjects homozygous for the insertion genotype, in members of the TwinsUK population cohort in order to assess whether the GluK4 deletion genotype could be a marker of protection against developing diseaseassociated cognitive deficits. Clinical data is available which allows the TwinsUK Cohort to be divided into subsets of individuals with various psychiatric and neurological disorders. Information is also available on current and past use of antidepressant, antipsychotic and antiepileptic medication. We hypothesized that carriers of the deletion allele would perform better than individuals homozygous for the insertion in tasks assessing specific aspects of cognition. We analysed cognitive test data, controlling for medication use, in members of the TwinsUK cohort with known GluK4 indel genotype status.
Materials and methods

Sample population
The TwinsUK cohort is a repository of approximately 12,000 monozygotic and dizygotic British twins who have been serially assessed for health traits. Procedures used for sample and data collection have been described previously (Spector et al., 2006) . TwinsUK was approved by the Guy's and St Thomas' Ethics Committee. 
Genotype Data
The aim of the UK10K project is to genome-wide sequence and deeply phenotype cohorts to assess the role of genetic variants in health and disease (Walter et al., 2015) .
Genotype data for the TwinsUK cohort was accessed from the European Genomephenome Archive (EGA; accession numbers EGAD00001000194 & EGAD00001000741) following a data access agreement with the UK10K project.
Permission to link the genotype and phenotype data was also granted by TREC.
Processing of next generation whole exome sequencing was performed by the Wellcome Trust Sanger Institute (Cambridge) using GATK and mapped to build 
Diagnostic groups and medication status
Information about clinical diagnosis and medication history was provided by TREC, Department of Twins Research and Genetic Epidemiology at King's College London.
The initial TwinsUK survey grouped participants into three diagnostic groupings; "learning disabilities", "mental health problems" and "other neurological disorders".
For the current analysis we retained the three main diagnostic groupings but excluded cases with learning disability or epilepsy from the "mental health problems" group because both learning disability and epilepsy are associated with specific patterns of cognitive deficits. The "learning disabilities" group included individuals both with and without co-morbid "mental health problems". Secondly all individuals with a diagnosis of epilepsy, some of whom were co-morbid with learning disabilities or mental health problems, were included in a single "epilepsy" group.
This gave a total of five diagnostic groups: no clinical phenotype (N=1071), learning disability (N=23); mental health problems (N=259); epilepsy (N=231); other neurological diseases (N=58). The "mental health problem" group included individuals with a diagnosis of clinical depression (163), bipolar disorder (2), anxiety and stressrelated disorders (31), eating disorders (15) Multivariate linear regression analyses were used to compare cognitive performance between the genotype groups. The derived diagnosis and medication variables were included as covariates. Z-scores of cognitive performance were generated and used to compare genotype, diagnosis and medication group relationships. Pearson's chisquared tests were performed to examine differences between diagnosis and medication status. As we hypothesized that carriers of the GluK4 deletion allele will perform better in the cognitive tests, statistical analysis was one-tailed and statistical significance was considered at p < 0.05. Table 1 presents the Pearson's correlation coefficients between each cognitive test outcome measure. Errors in paired associates learning (PAL) showed a significant positive correlation with spatial working memory task (SWM) errors (r > 0.39, p < 0.001), and with latency in the pattern recognition memory (PRM) (r > 0.26, p < 0.001) and reaction time (RTI) (r > 0.26, p < 0.001) tests. SWM errors also showed a significant positive association with RTI latency (r > 0.18, p < 0.01). As would be expected for two tests which assess mental response speed, PRM and RTI latency were also correlated (r > 0.24, p < 0.0001). There was no significant correlation between performance on the NART test and any of the CANTAB performance, supporting the distinction between general intelligence measured by NART and specific facets of cognition evaluated by the CANTAB tasks.
Results
Comparison of cognitive test outcome measures
Insert Table 1 Table 2 . As this grouping includes general intelligence, response times and errors in visual discriminatory we refer to this factor as 'general intelligence and visual discrimination'.
Insert Table 2 here. Insert Figure 1 here. Insert Table 3 here.
Cognitive performance and GluK4 genotype
Cognitive performance and diagnosis of neurological and mental disorders
Of the 1642 TwinsUK cohort members assessed, 571 individuals were reported to have a diagnosis of a mental health or neurological disorder. As these diagnoses were varied and often co-morbid, individuals with a diagnosis were categorized into the following Figure 1C ). Although the numbers within each group were relatively small, the effect sizes for these genotype differences in performance were relatively large.
Insert Table 4 here.
Cognitive performance and medication
Cohort members who reported a history of taking antipsychotic, antidepressant or antiepileptic medication were assessed in conjunction with diagnostic history ( Figure   1B ). Table 5 presents the number of individuals on each type of medication in total and split by genotype group. 195 individuals were reported to have taken medication and had a diagnosis of disease, corresponding to ~12% of the total number of individuals with diagnosis and medication status both available ( Figure 1B ). However, 74 individuals had no reported history of medication (they did not receive daily medication for over one month) but had a diagnosis. This corresponded to a ~4.5% of the total number of individuals with a diagnosis and medication status both available ( Figure   1B ).
To investigate the relationship between medication and the GluK4 indel genotype, individuals were categorized as taking antidepressants, other medication (antipsychotics, benzodiazepines, barbiturates) or no medication. Table 5 Insert Table 5 here.
Discussion
Impairments in working memory, attention and executive function are amongst the main cognitive deficits found in schizophrenia, bipolar disorder depression, and anxiety (Ferreri et al., 2011; Millan et al., 2012) . We tested the hypothesis that a deletion variant within GluK4 reported to confer protection against developing bipolar disorder would
show an association with better cognitive performance in a number of domain-specific cognitive tasks in unaffected individuals, and in individuals with "mental health problems", learning disabilities and individuals with "other brain diseases".
The cognitive profile of 1642 individuals from the TwinsUK study indicated a significant difference in spatial working memory performance between the DEL carriers and HOM INS genotype groups in the "mental health problems " group who almost entirely came under the umbrella diagnosis of "mood disorders", mainly depression and anxiety. Consistent with previous research, we discovered that DEL carriers made fewer errors in spatial working memory. We also found that DEL carriers who had a mental health illness showed better performance in 'visuo-spatial ability and mental speed' than HOM INS individuals.
Furthermore, DEL carriers within the 'the other neurological disorders' group showed better performance in the National Adult Reading Test, NART, than HOM INS individuals. As NART is a test which is commonly used to assess premorbid intelligence, i.e. more general cognitive ability, we might expect more general deficits which are not domain specific to be evident in a group who has neurological diseases which include Parkinson's disease, stroke, neuropathy, multiple sclerosis and migraine (McGurn et al., 2004) . However, our findings show that although there was overall no difference in NART between this diagnostic grouping and the others assessed, there was a highly significant genotype effect for NART scores, with DEL carriers performing better than HOM INS individuals. This would suggest that the GluK4 indel allele could be relevant to a broader disease phenotype than has previously been investigated and therefore has the potential to be a biological marker of function relevant to neurological disease prognosis. Future studies should aim to explore further the neuroprotective role of GluK4 deletion allele through both preclinical and neurological disease cohort studies.
The current study also provides evidence that an allele which modulates GluK4 protein abundance in both the frontal cortex and hippocampal regions such as the CA3 and dentate gyrus granule cells, is also involved in modulating memory function associated with hippocampal neuronal circuitry. We found that healthy and disease affected deletion carriers performed better in SWM, a test which involves hippocampal processing, i.e. the contextual component of spatial memory. These findings are consistent with the report that non-diseased GluK4 deletion carriers show increased hippocampal activity during a face-processing task (Whalley et al., 2009 ).
However, in contrast to our predictions, a difference in performance on the hippocampal-dependent CANTAB PAL test was not clearly shown. Nevertheless, DEL carriers who were identified as having a mental health problem performed better in the PCA-derived cognitive factor which included fewer errors in PAL, faster reaction time Knight et al., 2009; Singh et al., 2017) . One such large GWAS study recently reported an association between high frequency variants of small effect spanning the major histocompatibility complex (MHC) and risk for schizophrenia and bipolar disorder (International Schizophrenia et al., 2009) . Subsequent studies examining this locus identified multiple risk haplotypes composed of common alleles within the complement component 4 (C4) gene (Sekar et al., 2016) . Although the C4 gene is involved in the immune system classical complement cascade, the C4 protein is highly expressed in post synaptic compartments in neurons.
Of interest, members of a second complement cascade protein family (C1ql2 and C1ql3)
are also located at postsynaptic sites and are known to bind directly to the amino-terminal domains of kainite GluK2 and GluK4 KAR receptor subunits and hence regulate recruitment and function of ionotropic glutamate receptors at synapses (Matsuda, 2017) .
Unlike many other genes found associated with mental illness, GluK4 research has 
